Kairos Pharma, LTD. 8-K

What Happened

• On May 18, 2026, Kairos Pharma, Ltd. (KAPA) filed an 8-K announcing it issued a new investor presentation to be posted on its website (www.kairospharma.com) and presented at the LD Micro Invitational XVI in Los Angeles. CEO John Yu will present the slide deck to provide an update on the company’s clinical program and partnering activities. The presentation is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: May 18, 2026 (Form 8-K, accession 0001493152-26-024082).
• Event: LD Micro Invitational XVI, Los Angeles, CA, May 18–19, 2026; presentation delivered May 18, 2026.
• Presenter: John Yu, Chief Executive Officer.
• Presentation posted to Kairos Pharma’s website and included as Exhibit 99.1 to the filing.

Why It Matters

• The presentation provides a current, company‑issued update on Kairos’s clinical development progress and partnering efforts—key items investors watch for biotech companies.
• While the filing does not report financial results or corporate transactions, the update and public presentation could be a near-term information catalyst for investors tracking clinical milestones or business development activity.